Long-term follow-up data from the phase 1/2a PLX120-03 trial suggest plixorafenib can sustain durable responses in BRAF-altered primary central nervous system tumors. Presented as part of among-patient prespecified efficacy cohorts, the results reported objective response rates up to 80% in high-grade gliomas among BRAF V600E-mutated, MAPK inhibitor–naïve patients. Researchers also reported progression-free survival rates at 12 and 24 months of 56% and 33% respectively in the analyzed subgroup, with responses that persisted across extended treatment durations. Investigators framed the drug’s mechanism around BRAF V600 monomer inhibition designed to avoid paradoxical MAPK pathway activation seen with some BRAF inhibitors, supporting interest in longer-term single-agent CNS activity.
Get the Daily Brief